Enanta sells off over 50% of royalty payments from Mavyret in exchange for $200M

Katherine Lewin

News Reporter

Enanta Pharmaceuticals is selling off royalty payments from its AbbVie-partnered drug Mavyret, its biggest revenue driver, to a Canadian pension plan …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Enanta sells off over 50% of royalty payments from Mavyret in exchange for $200M

Katherine Lewin

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

Boehringer’s updated results in HER2-mutated lung cancer impress

Exclusive: Can AI replace animal testing? A new biotech launches to find out

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Enan­ta sells off over 50% of roy­al­ty pay­ments from Mavyret in ex­change for $200M

News Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Enanta sells off over 50% of royalty payments from Mavyret in exchange for $200M